Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer Hisashi TanakaKageaki TaimaSadatomo Tasaka Original Paper Open access 14 May 2019 Article: 57
Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21 Zumu LiangQingjie MouWeiguo Feng Original Paper 14 May 2019 Article: 56
Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma Takahiro KobayashiMasatomo MiuraNaoto Takahashi Original Paper 14 May 2019 Article: 55
Performance of a new system using a one-step nucleic acid amplification assay for detecting lymph node metastases in breast cancer Kenzo ShimazuTomonori TaneiShinzaburo Noguchi Original Paper 06 May 2019 Article: 54
Correction to: Expression of Concern: Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer Zhifeng LinLiwen XiongQiang Lin Correction 03 May 2019 Article: 53
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL) Hisashi HidakaNamiki IzumiYasuaki Arai Original Paper Open access 03 May 2019 Article: 52
Intra- and inter-observer variability in breast tumour bed contouring and the controversial role of surgical clips Giulia CorraoDamaris Patricia RojasMaria Cristina Leonardi Original Paper 29 April 2019 Article: 51
N-Glycosylation in progression of skin cancer Ling TangXiaoping ChenXiang Chen Review Article 29 April 2019 Article: 50
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease Ryota ShibakiShuji MurakamiYuichiro Ohe Original Paper 27 April 2019 Article: 49
Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction Fiorenza De RoseAntonella FogliataMarta Scorsetti Original Paper 25 April 2019 Article: 48
Timing of treatment in small-cell lung cancer Shruti BhandariDanh PhamGoetz Kloecker Short Communication 25 April 2019 Article: 47
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study) Naoki NagataHiromichi MaedaHideyuki Mishima Original Paper 24 April 2019 Article: 46
